The value of pharmacogenetic markers for personalized approach to the statins treatment

This review presents the most studied genetic markers which are risk factors for adverse drug reactions in patients who are treated with statins and/or associated with resistance to them. We have considered the possible practical advice for individual therapy with statins in patients with a known ge...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	N. V. Kokh, G. I. Lifshits
Formato:	article
Lenguaje:	RU
Publicado:	Scientific Сentre for Family Health and Human Reproduction Problems 2013
Materias:	slco1b1*5 hmgcr hmg-coa reductase inhibitors myopathy Science Q
Acceso en línea:	https://doaj.org/article/85a66bbe548a43ada191f55e6a9bef91
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:85a66bbe548a43ada191f55e6a9bef91
record_format	dspace
spelling	oai:doaj.org-article:85a66bbe548a43ada191f55e6a9bef912021-11-23T06:14:29ZThe value of pharmacogenetic markers for personalized approach to the statins treatment2541-94202587-9596https://doaj.org/article/85a66bbe548a43ada191f55e6a9bef912013-09-01T00:00:00Zhttps://www.actabiomedica.ru/jour/article/view/1668https://doaj.org/toc/2541-9420https://doaj.org/toc/2587-9596This review presents the most studied genetic markers which are risk factors for adverse drug reactions in patients who are treated with statins and/or associated with resistance to them. We have considered the possible practical advice for individual therapy with statins in patients with a known genotype. Identification of the gene variant SLCO1B15 is a risk factor for myopathy and rhabdomyolysis and HMGCR gene haplotype H7 is associated with less reduction in LDL cholesterol in patients receiving statins. Pathological effect of a particular genetic marker is modified by statin class or calculated personal dose. The use of pharmacogenetic testing will reduce the frequency of adverse outcomes of statins and make a prediction their performance in a specific patient. Howeverfurther studies on the translation of these personalized medicine tests to clinical practice are needed.N. V. KokhG. I. LifshitsScientific Сentre for Family Health and Human Reproduction Problemsarticleslco1b15hmgcrhmg-coa reductase inhibitorsmyopathyslco1b1*5hmgcrScienceQRUActa Biomedica Scientifica, Vol 0, Iss 5, Pp 176-180 (2013)
institution	DOAJ
collection	DOAJ
language	RU
topic	slco1b15 hmgcr hmg-coa reductase inhibitors myopathy slco1b15 hmgcr Science Q
spellingShingle	slco1b15 hmgcr hmg-coa reductase inhibitors myopathy slco1b15 hmgcr Science Q N. V. Kokh G. I. Lifshits The value of pharmacogenetic markers for personalized approach to the statins treatment
description	This review presents the most studied genetic markers which are risk factors for adverse drug reactions in patients who are treated with statins and/or associated with resistance to them. We have considered the possible practical advice for individual therapy with statins in patients with a known genotype. Identification of the gene variant SLCO1B1*5 is a risk factor for myopathy and rhabdomyolysis and HMGCR gene haplotype H7 is associated with less reduction in LDL cholesterol in patients receiving statins. Pathological effect of a particular genetic marker is modified by statin class or calculated personal dose. The use of pharmacogenetic testing will reduce the frequency of adverse outcomes of statins and make a prediction their performance in a specific patient. Howeverfurther studies on the translation of these personalized medicine tests to clinical practice are needed.
format	article
author	N. V. Kokh G. I. Lifshits
author_facet	N. V. Kokh G. I. Lifshits
author_sort	N. V. Kokh
title	The value of pharmacogenetic markers for personalized approach to the statins treatment
title_short	The value of pharmacogenetic markers for personalized approach to the statins treatment
title_full	The value of pharmacogenetic markers for personalized approach to the statins treatment
title_fullStr	The value of pharmacogenetic markers for personalized approach to the statins treatment
title_full_unstemmed	The value of pharmacogenetic markers for personalized approach to the statins treatment
title_sort	value of pharmacogenetic markers for personalized approach to the statins treatment
publisher	Scientific Сentre for Family Health and Human Reproduction Problems
publishDate	2013
url	https://doaj.org/article/85a66bbe548a43ada191f55e6a9bef91
work_keys_str_mv	AT nvkokh thevalueofpharmacogeneticmarkersforpersonalizedapproachtothestatinstreatment AT gilifshits thevalueofpharmacogeneticmarkersforpersonalizedapproachtothestatinstreatment AT nvkokh valueofpharmacogeneticmarkersforpersonalizedapproachtothestatinstreatment AT gilifshits valueofpharmacogeneticmarkersforpersonalizedapproachtothestatinstreatment
_version_	1718417144119558144

The value of pharmacogenetic markers for personalized approach to the statins treatment

Ejemplares similares